The premature onset of malignant coronary artery disease within the South Asian demographic represents a critical epidemiological crisis. While ischemic events remain exceedingly rare in Western cohorts under age 30, myocardial infarctions drive an astonishing 29% of all premature deaths in young Indians under 30, contrasted with a mere 2% in the United States.

Relying on traditional stress testing frequently provides false reassurance to clinicians, as up to 40% of asymptomatic young patients with completely normal functional stress tests display severe subclinical calcified plaque burdens. This diagnostic discordance emphasizes the need to replace antiquated ischemic testing paradigms with anatomically driven, tracking protocols.

Addressing this clinical practice gap during a session at the World Congress of Cardiovascular-Kidney-Metabolic Medicine (WCCKMM 2026) in the Tagore Hall, Dr. Enas A. Enas, Founding President of the CADI Research Foundation, introduced aggressive prevention strategies.

Dr. Enas clarified that South Asian ethnicity operates as an independent risk-enhancing factor, accelerating atherogenesis five to ten years earlier than in other ethnic cohorts. Data from the London Life Sciences prospective study following 25,000 individuals over 20 years confirms that conventional European and American risk equations systematically underestimate cardiovascular vulnerability in this population.

Genetics loads the metabolic gun, but rapid environmental transitions pull the trigger, altering atherogenic expressions without shifting baseline DNA sequences. Atherosclerotic plaques begin contracting Indian coronary arteries as early as age five, fueled by high circulating levels of Lipoprotein(a) and an atherogenic dyslipidemia marked by elevated low-density lipoprotein (LDL) particle counts.

To achieve the dramatic 80% reduction in coronary mortality observed in Western nations over the last 50 years, clinical frameworks must prioritize aggressive, early primordial and primary interventions. Dr. Enas asserted that the baseline target for total cholesterol in South Asians should be adjusted down to 140 mg/dL, with non-HDL targets restricted below 100 mg/dL to halt ongoing vascular tracking.

Clinicians must mandate a comprehensive lipid profile and Lipoprotein(a) screening between ages 5 and 10 to expose hereditary cardiorenal metabolic risks early. Furthermore, a non-contrast coronary artery calcium (CAC) scan should be universally performed by age 30 to identify silent macrovascular atherosclerosis before the first ischemic event occurs. Therapeutic strategies must initiate high-intensity statin therapy below age 40 if subclinical plaque is visualized, regardless of whether a patient appears low risk on standard calculators. Emerging therapeutics like pelacarsen offer additional utility, demonstrating a 95% reduction in Lipoprotein(a) levels to arrest premature atherothrombotic cascades.

Why do international guidelines continue to recommend late-stage screening algorithms when the biological tracking of premature South Asian vascular failure begins in early childhood? Dr. Enas left the specialist assembly to confront this systemic prevention failure.

TheRightDoctors | Official Digital Knowledge Partner | WCCKMM 2026